Unknown

Dataset Information

0

Racial/ethnic disparities in initiation and persistent use of anti-dementia medications.


ABSTRACT:

Background

Racial/ethnic disparities in anti-dementia medications use in longitudinally followed research participants are unclear.

Methods

The study included initially untreated participants followed in National Alzheimer's Coordinating Center Uniform Data Set who were ≥65 at baseline with Alzheimer's disease dementia.

Outcomes

Outcomes for acetylcholinesterase inhibitor (AChEI) treatment included (1) any new AChEI treatment during follow-up, and (2) persistence of treatment during follow-up categorized into: intermittent treatment (< 50% follow-ups reporting treatment), persistent (≥50% follow-ups), and always treated. Outcomes for memantine treatment were similarly constructed.

Results

Controlling for participant characteristics, Black and Hispanic participants remained less likely than White participants to report any new AChEI or memantine treatment during follow-up. Among those who reported new treatment during follow-up, both Black and Hispanic participants were less likely than White participants to be persistently treated with AChEI and memantine.

Discussion

Substantial racial/ethnic treatment disparities remain in controlled settings of longitudinal research in which participants have access to dementia experts, suggesting wider disparities in the larger community.

SUBMITTER: Zhu CW 

PROVIDER: S-EPMC9402814 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Racial/ethnic disparities in initiation and persistent use of anti-dementia medications.

Zhu Carolyn W CW   Neugroschl Judith J   Barnes Lisa L LL   Sano Mary M  

Alzheimer's & dementia : the journal of the Alzheimer's Association 20220225 12


<h4>Background</h4>Racial/ethnic disparities in anti-dementia medications use in longitudinally followed research participants are unclear.<h4>Methods</h4>The study included initially untreated participants followed in National Alzheimer's Coordinating Center Uniform Data Set who were ≥65 at baseline with Alzheimer's disease dementia.<h4>Outcomes</h4>Outcomes for acetylcholinesterase inhibitor (AChEI) treatment included (1) any new AChEI treatment during follow-up, and (2) persistence of treatme  ...[more]

Similar Datasets

| S-EPMC8959738 | biostudies-literature
| S-EPMC6199984 | biostudies-literature
| S-EPMC8652993 | biostudies-literature
| S-EPMC8008426 | biostudies-literature
| S-EPMC6338306 | biostudies-literature
| S-EPMC3307916 | biostudies-literature
| S-EPMC10564412 | biostudies-literature
| S-EPMC10475144 | biostudies-literature
| S-EPMC6873154 | biostudies-literature
| S-EPMC5554114 | biostudies-literature